$KRYS (-0,04 %)

However, earnings and profit growth are somewhat better than at Novo.

"Buy the dip"

Small additional purchase

$KRYS (-0,04 %)

Hello my dears,

How crazy the stock market can be.

Here you present top figures but don't reach the estimates. And the share is punished like a Novo Nordisk.

I remain invested, perhaps even a good time to buy more.

What do you think?

@Memo0606

Krystal Biotech, Inc ( KRYS ) reported second quarter earnings that were up from the same period last year, but missed Wall Street estimates.

The company's profit totaled $38.33 million, or $1.29 per share. In the previous year, the profit amounted to 15.57 million US dollars or 0.53 US dollars per share.

On average, analysts had expected earnings of USD 1.44 per share. The analysts' estimates generally do not include any special effects.

The company's turnover rose by 36.7% to USD 96.04 million in this period compared to USD 70.28 million in the previous year.

The profits of Krystal Biotech, Inc. at a glance (GAAP):

-Net income: $38.33 million compared to $15.57 million in the prior year.

-EPS: USD 1.29 compared to USD 0.53 in the previous year.

-Revenue: USD 96.04 million compared to USD 70.28 million in the previous year.

https://www.rttnews.com/3561343/krystal-biotech-inc-q2-profit-advances-but-misses-estimates.aspx

$KRYS (-0,04 %)
@Memo0606

PITTSBURGH,July 25, 2025 (GLOBE NEWSWIRE) -Krystal Biotech, Inc. (the "Company") (NASDAQ: KRYS) announced today that on July 24, 2025, Japan's July 24, 2025, Japan's Ministry of Health, Labor and Welfare (MHLW) granted marketing approval for VYJUVEK ® (beremagene geperpavec-svdt) for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB) from birth. VYJUVEK is the first genetically approved drug inJapandeveloped for the treatment of DEB, it aims to address the root cause of the disease. It delivers functional copies of the human COL7A1 gene to enable wound healing and sustained functional expression of collagen protein type VII upon re-dosing. The Japanese approval allows for dosing at home or in a medical facility, with the possibility of administration by patients or their relatives.

According to the MHLW approval, VYJUVEK is intended exclusively for use in patients diagnosed with dystrophic epidermolysis bullosa. Genetic testing is not required for treatment.

https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-approval-vyjuvekr-japans-ministry

Hello, today I have attached my two year old portfolio.

I made some mistakes that I regret a lot but that's not the point today.

I'm interested in whether I've made the titles $OSK (+0 %) & $KRYS (-0,04 %) should sell.

I've simply invested too little to make big profits there, although I'm currently making quite a decent return, but as I said, I've simply put in too little cash...

I believe in both stocks, but I also want to slim down my portfolio a bit and I'm currently saving up cash for the next setback so that I can invest more money in existing stocks.

So would you hold the stocks and add to them in the event of a setback or would you say sell and then shift into existing stocks with the additional money you have freed up?

Many thanks in advance :)

PS: If you still feel like it, you are welcome to comment on the portfolio, I still have a lot to learn and criticism and improvements are always welcome ;-)

Dear community I have created cash

I would like to buy more

these values are available

$PRY (-0,09 %)

$KRYS (-0,04 %)

$ATCO B (-0,12 %)

$NBIX (-0,02 %)

$CACI (-0,07 %)

$4063 (-0,69 %) SHIN ETSU

what do you think

Could not resist

Hello folks

would you find it useful $JNJ (-0,31 %) to sell and $KRYS (-0,04 %) to buy

I think $KRYS (-0,04 %) has a very good pipeline and looks fair

what is your general opinion on $KRYS (-0,04 %)

$KRYS (-0,04 %)

Hello my dears here is a great profit growth at an acceptable P/E ratio.

In the USA, demand for Krystal Biotech's gene therapy Vyjuvek is already extremely high. No wonder, the product is a game changer for the treatment of epidermolysis bullosa dystrophica (EBD), also known as "butterfly disease". Now sufferers in Europe can also justifiably hope for approval in the near future.

This is because Krystal Biotech has received a positive vote from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), which supports EU approval of Vyjuvek. Now all that remains is for the European Commission to give the final green light. Krystal Biotech expects the decision in the second quarter of the current year.

"We are delighted to be able to offer DEB patients the first treatment that corrects the genetic defect and really changes their lives," says Dr. Cristina Has, Professor and Head of the Clinic for Genodermatoses in the Department of Dermatology at the University of Freiburg, looking optimistically towards approval. "Vyjuvek is a milestone because it addresses the first stage of the complex pathophysiology of DEB. It is amazing how simple and non-invasive it is to use, even in infants."

In May 2023, the US Food and Drug Administration (FDA) has already granted marketing authorization for Krystal Biotech's gene therapy. The launch went so well that the biotech company even reported earnings per share of USD 3.12 for 2024. Turnover increased by a whopping 473% to 290.5 million dollars compared to 2023.

CONCLUSION

Vyjuvek has quickly led Krystal Biotech into the black. This is despite the fact that the company is pushing ahead with other exciting pipeline assets that are cost-intensive. Larger setbacks remain interesting entry opportunities for speculative investors with the current SHAREHOLDER recommendation (up 157% since its launch in mid-February 2023).

https://www.deraktionaer.de/artikel/pharma-biotech/aktionaer-hot-stock-krystal-biotech-gamechanger-bald-auch-in-europa-20375846.html

https://www.deraktionaer.de/artikel/pharma-biotech/aktionaer-hot-stock-krystal-biotech-gamechanger-bald-auch-in-europa-20375846.html

$KRYS (-0,04 %)

Krystal Biotech, Inc. ( KRYS ) announced fourth quarter earnings that were up from the same period last year

The company's net income totaled $45.48 million, or $1.52 per share. In the previous year, it amounted to 8.69 million US dollars or 0.30 US dollars per share.

The company's turnover increased by 116.3 % from 42.14 million US dollars in the previous year to 91.14 million US dollars in this period.

The results of Krystal Biotech, Inc. at a glance (GAAP):

-Profit: $45.48 million compared to $8.69 million last year.

-EPS: $1.52 vs. $0.30 last year.

-Revenue: $91.14 million compared to $42.14 million last year.

https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-fourth-quarter-and-full-year-2024

https://www.rttnews.com/3514054/krystal-biotech-inc-bottom-line-advances-in-q4.aspx

$KRYS (-0,04 %)

Summary

• Krystal Biotech's VYJUVEK, a breakthrough gene therapy for DEB, generated revenues of $83.8m in 3Q 2024, doubling from 4Q 2023.
• At 57x 2024 earnings, Krystal's stock appears expensive but is expected to double in earnings by 2025.
• With the upcoming expansion of the EU and Japan market, Krystal seems poised to exceed analysts' growth expectations.
• VYJUVEK is a potential blockbuster as Krystal targets $1 billion in sales with its first commercialized drug.
• Krystal is capitalizing on its niche in redosable gene therapy with a compelling pipeline focused on multiple genetic diseases.

Krystal Biotech: Blockbuster-Ambitionen für topische Gentherapie (NASDAQ:KRYS) | Auf der Suche nach Alpha